HK1098372A1 - Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein - Google Patents

Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein

Info

Publication number
HK1098372A1
HK1098372A1 HK07104918.4A HK07104918A HK1098372A1 HK 1098372 A1 HK1098372 A1 HK 1098372A1 HK 07104918 A HK07104918 A HK 07104918A HK 1098372 A1 HK1098372 A1 HK 1098372A1
Authority
HK
Hong Kong
Prior art keywords
inhibitor
pharmaceutical composition
fusion protein
benzodiazepine derivative
rsv fusion
Prior art date
Application number
HK07104918.4A
Other languages
English (en)
Inventor
Kenneth Powell
Richard Kelsey
Malcolm Carter
Dagmar Alber
Lara Wilson
Elisa Henderson
Phil Chambers
Debra Taylor
Stan Tyms
Verity Dowdell
Original Assignee
Arrow Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrow Therapeutics Ltd filed Critical Arrow Therapeutics Ltd
Publication of HK1098372A1 publication Critical patent/HK1098372A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK07104918.4A 2004-03-19 2007-05-08 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein HK1098372A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0406282.4A GB0406282D0 (en) 2004-03-19 2004-03-19 Therapeutic compounds
PCT/GB2005/001018 WO2005089769A1 (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibit or of the rsv fusion protein

Publications (1)

Publication Number Publication Date
HK1098372A1 true HK1098372A1 (en) 2007-07-20

Family

ID=32118068

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07104918.4A HK1098372A1 (en) 2004-03-19 2007-05-08 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein

Country Status (19)

Country Link
US (1) US8853204B2 (da)
EP (1) EP1727550B1 (da)
JP (1) JP4940128B2 (da)
KR (2) KR101292431B1 (da)
CN (1) CN1933842A (da)
AT (1) ATE437643T1 (da)
AU (2) AU2005224157B2 (da)
BR (1) BRPI0507654A (da)
CA (1) CA2558112C (da)
CY (1) CY1109523T1 (da)
DE (1) DE602005015686D1 (da)
DK (1) DK1727550T3 (da)
ES (1) ES2327757T3 (da)
GB (1) GB0406282D0 (da)
HK (1) HK1098372A1 (da)
PL (1) PL1727550T3 (da)
PT (1) PT1727550E (da)
RU (1) RU2388476C2 (da)
WO (1) WO2005089769A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0406279D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
CA2669705A1 (en) * 2006-11-21 2008-05-29 Novartis Ag Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure
GB201506448D0 (en) 2015-04-16 2015-06-03 Univ Durham An antimicrobial compound
LT3324977T (lt) 2015-07-22 2022-10-25 Enanta Pharmaceuticals, Inc. Benzodiazepino dariniai kaip rsv inhibitoriai
US20170226129A1 (en) 2016-01-15 2017-08-10 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
GB201613942D0 (en) * 2016-08-15 2016-09-28 Univ Of Durham The An antimicrobial compound
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
CA3065368A1 (en) 2017-02-16 2018-08-23 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
BR112020006334A2 (pt) 2017-09-29 2020-09-24 Enanta Pharmaceuticals, Inc. combinação de agentes farmacêuticos como inibidores de rsv
WO2019094920A1 (en) * 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
CA3080138A1 (en) * 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
WO2019199908A1 (en) 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
UY38614A (es) 2019-03-18 2020-10-30 Enanta Pharm Inc Derivados de benzodiazepinas como inhibidores del rsv
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
GB201911944D0 (en) 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
CA3153297A1 (en) 2019-10-04 2021-04-08 Adam SZYMANIAK Antiviral heterocyclic compounds
GB201915273D0 (en) * 2019-10-22 2019-12-04 Reviral Ltd Pharmaceutical compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
MX2023009961A (es) 2021-02-26 2023-09-05 Enanta Pharm Inc Compuestos heterociclicos antivirales.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324794A (en) * 1980-08-26 1982-04-13 Research Triangle Institute Inhibition of respiratory syncytial virus-induced cell fusion by amidino compounds
EP0491218A1 (en) * 1990-12-17 1992-06-24 F. Hoffmann-La Roche Ag Benzodiazepinones
NZ500029A (en) * 1997-04-07 2001-02-23 Axys Pharm Inc Compounds and compositions of carboxamide derivatives associated with the treatment of rheumatoid arthritis, conjunctivitis and/ or syncytial virus infections
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
US6506738B1 (en) * 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
US6919331B2 (en) * 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
PL369432A1 (en) * 2001-12-10 2005-04-18 Bristol-Myers Squibb Company Bis hydrochloride monohydrate salt of rsv fusion inhibitor
JP2004107494A (ja) * 2002-09-18 2004-04-08 National Institute For Materials Science 熱可塑性層状アルキルシロキサンとその製造方法
MXPA05002871A (es) * 2002-09-20 2005-10-05 Arrow Therapeutics Ltd Derivados de benzodiazaepina y composiciones farmaceuticas que los contienen.
GB0406279D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds

Also Published As

Publication number Publication date
PL1727550T3 (pl) 2010-01-29
KR20070009629A (ko) 2007-01-18
DE602005015686D1 (de) 2009-09-10
WO2005089769A1 (en) 2005-09-29
CA2558112C (en) 2014-07-29
KR20130042593A (ko) 2013-04-26
GB0406282D0 (en) 2004-04-21
PT1727550E (pt) 2009-08-28
RU2388476C2 (ru) 2010-05-10
JP2007529489A (ja) 2007-10-25
DK1727550T3 (da) 2009-10-19
EP1727550B1 (en) 2009-07-29
ATE437643T1 (de) 2009-08-15
KR101292431B1 (ko) 2013-07-31
CN1933842A (zh) 2007-03-21
US8853204B2 (en) 2014-10-07
BRPI0507654A (pt) 2007-07-10
AU2005224157A1 (en) 2005-09-29
AU2005224157B2 (en) 2009-05-28
ES2327757T3 (es) 2009-11-03
AU2009212826A1 (en) 2009-09-17
CA2558112A1 (en) 2005-09-29
CY1109523T1 (el) 2014-08-13
US20070142403A1 (en) 2007-06-21
EP1727550A1 (en) 2006-12-06
JP4940128B2 (ja) 2012-05-30
RU2006136880A (ru) 2008-04-27

Similar Documents

Publication Publication Date Title
PT1727551E (pt) Composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteína de fusão do rsv
HK1098372A1 (en) Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein
AU2003264038A1 (en) Combination pharmaceutical agents as inhibitors of hcv replication
WO2006128184A3 (en) Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
WO2007139856A3 (en) Heterobicyclic metalloprotease inhibitors
MXPA05002871A (es) Derivados de benzodiazaepina y composiciones farmaceuticas que los contienen.
UA89220C2 (ru) Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
PT1261586E (pt) Inibidores da dipeptidil peptidase iv à base de pirrolidina condensada com ciclopropilo, processos para a sua preparação e sua utilização
CA2504735A1 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2000055124A3 (en) Novel compounds and compositions as protease inhibitors
AU2002338806A1 (en) Pharmaceutical combinations of pde-v inhibitors and other agents
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
AU2003201071A1 (en) Stable pharmaceutical compositions comprising ace inhibitor(s)
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
WO2004016741A3 (en) Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
AU2003227186A1 (en) Spiro derivatives and adhesion molecule inhibitors comprising the same as the active ingredient
AP2203A (en) Peptide derivative fusion inhibitors of HIV infection.
AU2001252419A1 (en) Thrombin inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150318